Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study.

ABSTRACT:

Background

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is aimed at addressing the urgent need to find effective treatments for patients hospitalised with suspected or confirmed COVID-19. The trial has had many successes, including discovering that dexamethasone is effective at reducing COVID-19 mortality, the first treatment to reach this milestone in a randomised controlled trial. Despite this, it continues to use standard or 'fixed' randomisation to allocate patients to treatments. We assessed the impact of implementing response adaptive randomisation within RECOVERY using an array of performance measures, to learn if it could be beneficial going forward. This design feature has recently been implemented within the REMAP-CAP platform trial.

Methods

Trial

SUBMITTER: Sirkis T 

PROVIDER: S-EPMC9356442 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature